CenterBook Partners LP Takes $14.41 Million Position in Natera, Inc. (NASDAQ:NTRA)

CenterBook Partners LP bought a new position in Natera, Inc. (NASDAQ:NTRA - Free Report) during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 101,922 shares of the medical research company's stock, valued at approximately $14,413,000. Natera accounts for 0.9% of CenterBook Partners LP's investment portfolio, making the stock its 18th largest holding. CenterBook Partners LP owned about 0.08% of Natera at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of NTRA. Price T Rowe Associates Inc. MD grew its position in shares of Natera by 134.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company's stock valued at $1,067,327,000 after acquiring an additional 3,871,862 shares during the period. JPMorgan Chase & Co. boosted its holdings in Natera by 43.7% in the 4th quarter. JPMorgan Chase & Co. now owns 6,701,425 shares of the medical research company's stock valued at $1,060,836,000 after purchasing an additional 2,036,396 shares during the period. Norges Bank bought a new stake in Natera in the 4th quarter valued at about $224,040,000. Vanguard Group Inc. lifted its holdings in shares of Natera by 7.7% during the 4th quarter. Vanguard Group Inc. now owns 12,316,470 shares of the medical research company's stock worth $1,949,697,000 after acquiring an additional 879,463 shares during the period. Finally, Wellington Management Group LLP lifted its holdings in shares of Natera by 15.7% during the 4th quarter. Wellington Management Group LLP now owns 3,240,041 shares of the medical research company's stock worth $512,898,000 after acquiring an additional 439,778 shares during the period. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director Gail Boxer Marcus sold 4,299 shares of Natera stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the sale, the director owned 8,118 shares in the company, valued at approximately $1,358,628.48. This trade represents a 34.62% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Solomon Moshkevich sold 3,000 shares of the firm's stock in a transaction dated Tuesday, July 1st. The stock was sold at an average price of $166.77, for a total value of $500,310.00. Following the completion of the sale, the insider directly owned 130,205 shares in the company, valued at approximately $21,714,287.85. The trade was a 2.25% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,272 shares of company stock valued at $8,345,368 in the last ninety days. Company insiders own 7.60% of the company's stock.

Natera Price Performance

Shares of NTRA stock traded down $1.56 during trading hours on Wednesday, reaching $148.29. 1,537,923 shares of the stock were exchanged, compared to its average volume of 1,423,533. The business's fifty day moving average is $160.96 and its two-hundred day moving average is $158.33. Natera, Inc. has a 12-month low of $92.14 and a 12-month high of $183.00. The firm has a market capitalization of $20.25 billion, a P/E ratio of -100.88 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. The firm had revenue of $501.83 million during the quarter, compared to the consensus estimate of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The firm's quarterly revenue was up 36.5% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.56) earnings per share. As a group, equities research analysts predict that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Analyst Ratings Changes

NTRA has been the subject of a number of research analyst reports. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a research report on Saturday, May 17th. Barclays raised their price target on shares of Natera from $160.00 to $190.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. UBS Group raised their price target on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Finally, Piper Sandler lifted their price objective on shares of Natera from $205.00 to $210.00 and gave the company an "overweight" rating in a report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $184.63.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.